Swiss biotechnology with solid development: Economic climate and industry trends

Thursday, June 18, 2020 @ 11:30 am

The Swiss biotechnology industry performed well in 2019, regardless of the macroeconomic and external environment. The industry proved to be resistant to the increased geopolitical, trade policy and tariff challenges: Financing remained sound, revenues increased and mergers and acquisitions continued. At the same time, the industry became even more diverse: gene therapy, artificial intelligence and the production of advanced biologicals developed into complementary strengths.

Read the full German article by Michael Altorfer, CEO Swiss Biotech Association, and Jürg Zürcher, Partner and Biotechnology Leader Germany, Switzerland and Austria, Ernst & Young Zurich:

Download PDF "Schweizer Biotechnologie mit solider Entwicklung“ – CHEManager 6/2020
or go to online version of the magazine CHEManager 6/2020 - Schweizer Biotechnologie mit solider Entwicklung

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Vandria becoming clinical stage company: First clinical trial for neurodegenerative disorders

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024

BioCopy's CEO Matthias Wiedenfels among Germany's biotech pioneers of the coming decade

BioCopy CEO Matthias Wiedenfels honored as winner of "Germany's 30 by 2030" award.
December 17, 2024

The co-founders of AlphaMol are ranked as the "top 2% scientists" in the world

December 16, 2024

Porton Pharma Solutions: Collaboration with Aojin Life Sciences in China and USA

December 13, 2024

MedScienceSwiss: Combatting antibiotic-resistant bacteria with “Plan B”

MedScienceSwiss is developing a non-pharmaceutical therapy for the treatment of antibiotic-resistant bacteria. The goal: to significantly reduce the number of deaths in hospitals due to nosocomial (difficult-to-treat) infections. The technology is not only intended to serve as an alternative to the current plan A (antibiotics), but also to function as a general approach to the treatment of resista
December 3, 2024